TipRanks
Bio-UV Group SA (FR:ALTUV)
:ALTUV
France Market
Want to see FR:ALTUV full AI Analyst Report?

Bio-UV Group SA (ALTUV) AI Stock Analysis

0 Followers

Top Page

FR:ALTUV

Bio-UV Group SA

(ALTUV)

Select Model
Select Model
Select Model
Neutral 60 (OpenAI - Gpt-5.6Sol)
Rating:60Neutral
Price Target:
€1.00
▼(-26.47% Downside)
Action:Reiterated
Date:08/10/26
The score is driven primarily by improving and consistently positive cash generation and a reasonably supported balance sheet. This is tempered by declining revenue and uneven profitability (including weak gross profit in 2025), while technicals are only modestly constructive and valuation (P/E ~21.8 with no dividend yield provided) offers limited support.
Positive Factors
Cash Generation
Consistent operating cash generation and accelerating free cash flow improve liquidity and reduce reliance on external funding. This supports ongoing investment, service capability, and customer delivery while giving management greater flexibility through the next several quarters.
Negative Factors
Revenue Decline
Repeated annual revenue contraction limits operating leverage and makes it harder to spread fixed engineering, manufacturing, and support costs over a growing base. Unless demand returns, weaker scale can constrain investment capacity and keep earnings recovery dependent on cost control.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash Generation
Consistent operating cash generation and accelerating free cash flow improve liquidity and reduce reliance on external funding. This supports ongoing investment, service capability, and customer delivery while giving management greater flexibility through the next several quarters.
Read all positive factors

Bio-UV Group SA (ALTUV) vs. iShares MSCI France ETF (EWQ)

Bio-UV Group SA Business Overview & Revenue Model

Company Description
Based in Lunel, France, BIO-UV Group S.A. specializes in the conception, production, and commercialization of ultraviolet (UV) light systems for the purification of water and disinfection of surfaces. Serving both private individuals and professio...
How the Company Makes Money
Bio-UV Group SA makes money primarily by selling water treatment equipment and associated services across its target markets. Key revenue streams include: (1) Sale of UV disinfection systems and related treatment units: the company generates reven...

Bio-UV Group SA Financial Statement Overview

Summary
Cash flow is the main strength (consistently positive operating cash flow and accelerating free cash flow in 2025), and leverage looks manageable with improved equity in 2025. Offsetting this, revenue has declined in 2023–2025 and profitability is uneven, including unusually weak gross profit in 2025 versus prior years, which reduces confidence in earnings quality.
Income Statement
52
Neutral
Balance Sheet
63
Positive
Cash Flow
72
Positive
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue35.59M35.90M39.58M43.13M51.29M33.46M
Gross Profit1.46M2.00M24.09M25.58M4.71M1.84M
EBITDA520.21K1.60M4.18M4.43M6.38M3.35M
Net Income187.83K836.34K31.36K124.89K2.42M689.38K
Balance Sheet
Total Assets71.98M69.21M66.09M71.41M74.08M81.12M
Cash, Cash Equivalents and Short-Term Investments7.75M10.18M3.87M2.73M1.98M10.57M
Total Debt18.44M20.23M23.99M28.27M29.15M30.74M
Total Liabilities30.84M28.68M33.40M39.19M41.74M50.43M
Stockholders Equity41.08M40.47M32.69M32.22M32.24M30.52M
Cash Flow
Free Cash Flow1.82M3.00M5.00M4.28M476.03K571.69K
Operating Cash Flow3.33M4.63M6.90M6.24M2.70M3.30M
Investing Cash Flow-1.53M-1.60M-1.87M-1.95M-8.95M-20.70M
Financing Cash Flow-3.05M3.37M-3.73M-3.57M-2.50M15.53M

Bio-UV Group SA Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.36
Price Trends
50DMA
1.30
Negative
100DMA
1.33
Negative
200DMA
1.36
Negative
Market Momentum
MACD
-0.05
Positive
RSI
22.79
Positive
STOCH
10.74
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALTUV, the sentiment is Negative. The current price of 1.36 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.30, and above the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 22.79 is Positive, neither overbought nor oversold. The STOCH value of 10.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALTUV.

Bio-UV Group SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$10.79B15.437.44%2.01%2.89%-14.66%
60
Neutral
€15.14M114.95―1.96%-5.75%-78.66%
57
Neutral
€1.32B9.9411.53%1.57%-2.88%24.77%
55
Neutral
€575.67M32.312.68%1.62%2.29%-59.18%
55
Neutral
€22.64B18.3417.55%4.87%-0.13%12.40%
42
Neutral
€11.57M-0.8224.22%―-1.54%-68.96%
* Industrials Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ALTUV
Bio-UV Group SA
1.12
-0.50
-30.75%
FR:DBG
Derichebourg
8.25
2.88
53.72%
FR:SCHP
Seche Environnement
74.00
1.83
2.54%
FR:VIE
Veolia Environnement
30.81
3.07
11.08%
FR:OREGE
Orege SA
0.23
-0.06
-21.84%
FR:GPE
Groupe Pizzorno Environnement SA
62.05
7.13
12.98%

Bio-UV Group SA Corporate Events

BIO-UV Group Holds Revenue Steady, Narrows Margins but Reaffirms 2026 Growth Targets
Sep 18, 2026
BIO-UV Group reported first-half 2026 revenue of €20.1m, broadly flat year-on-year, as robust growth in its Solutions and Services Aftermarket divisions offset a 13% decline in Products sales amid salesforce reorganisation and weaker French...
BIO-UV Group Details Mid-2026 Liquidity Contract Activity
Sep 8, 2026
BIO-UV Group reported the mid-2026 status of the liquidity contract it has entrusted to All Invest for its shares listed on Euronext Growth. As of 30 June 2026, the liquidity account held 65,162 shares and a cash balance of €77,350.38, compa...
BIO-UV Group Holds Revenue Steady as Services and Solutions Drive 2026 Rebound
Jul 23, 2026
BIO-UV Group reported first-half 2026 revenue of €20.1 million, essentially flat year-on-year, as double-digit growth in Services After-Sales and a 4% rebound in the Solutions division offset a 13% decline in Products tied to salesforce reo...
BIO-UV Group Holds H1 Revenue Stable and Confirms 2026 Growth Targets
Jul 22, 2026
BIO-UV Group reported first-half 2026 revenue of €20.1m, almost stable year-on-year, with a strong 10% increase in Services After-Sales and a 4% recovery in Solutions offset by a 13% decline in Products. The services division, which benefit...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 10, 2026